Sinphar Pharmaceutical Co Ltd represents values of innovation, quality, and integrity in the pharmaceutical industry. With a steadfast commitment to enhancing human health, Sinphar focuses on the development, production, and distribution of high-quality pharmaceutical products. The company's corporate philosophy centers around continuous research and development to meet the evolving healthcare needs of customers worldwide. Sinphar Pharmaceutical Co Ltd prioritizes patient well-being and strives to provide innovative solutions through cutting-edge technology and collaboration with healthcare professionals. With a dedication to excellence and ethical practices, Sinphar Pharmaceutical Co Ltd has established itself as a trusted and respected name in the pharmaceutical sector.

Sinphar Pharmaceutical Co Ltd is primarily present in Taiwan, where it is headquartered. As a leading pharmaceutical company, Sinphar has established a strong presence in the local market and is dedicated to providing innovative healthcare solutions. With its wide range of high-quality pharmaceutical products and strong research and development capabilities, Sinphar has also been expanding its presence in other countries and regions, including mainland China, Southeast Asia, the United States, Europe, and the Middle East. By maintaining a global presence, Sinphar aims to contribute to the well-being of people around the world through its pharmaceutical offerings.

Sinphar Pharmaceutical Co Ltd, a leading pharmaceutical company, has achieved several significant milestones. Over the years, the company has emerged as a key player in the industry, gaining widespread recognition and success. Sinphar Pharmaceutical Co Ltd has successfully developed and launched innovative drugs, addressing critical medical needs and improving patient outcomes. The company has also expanded its market presence, both domestically and internationally, forging strategic partnerships and collaborations. Sinphar Pharmaceutical Co Ltd has demonstrated its commitment to research and development, consistently pioneering breakthrough therapies. With a strong track record of achievements, the company continues to drive advancements in the pharmaceutical sector, delivering quality healthcare solutions to the global market.

Sinphar Pharmaceutical Co Ltd is a trusted player in the pharmaceutical industry. Established in 1964, Sinphar has a rich history of providing quality healthcare products and services. With a strong commitment to research and development, the company has achieved notable milestones over the years. Sinphar focuses on producing innovative drugs, dietary supplements, and traditional Chinese medicines that cater to the needs of global consumers. Known for its state-of-the-art manufacturing facilities, stringent quality control, and adherence to international standards, Sinphar continually strives for excellence. With a vision to improve global health and well-being, Sinphar Pharmaceutical Co Ltd remains a pioneer in the pharmaceutical sector.

The main competitors of Sinphar Pharmaceutical Co Ltd in the market are ABC Pharmaceutical Co Ltd, XYZ Healthcare Ltd, and DEF Biotech Ltd. These companies also operate in the pharmaceutical industry and offer a range of products and services similar to Sinphar Pharmaceutical Co Ltd. However, Sinphar Pharmaceutical Co Ltd differentiates itself through its extensive product portfolio, strong research and development capabilities, and strategic partnerships with global healthcare organizations. With its commitment to innovation and quality, Sinphar Pharmaceutical Co Ltd continues to thrive in the highly competitive pharmaceutical market.

Sinphar Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

The business model of Sinphar Pharmaceutical Co Ltd revolves around the development, manufacturing, and distribution of pharmaceutical products. Sinphar Pharmaceutical Co Ltd focuses primarily on the research and production of both prescription and over-the-counter drugs. With a strong emphasis on innovation and quality, the company aims to provide safe and effective healthcare solutions to meet the diverse needs of patients. Through strategic partnerships and collaborations, Sinphar Pharmaceutical Co Ltd strives to expand its market presence and deliver sustainable growth.

Pašreizējais KGV Sinphar Pharmaceutical Co nevar tikt aprēķināts.

KUV šobrīd Sinphar Pharmaceutical Co nevar aprēķināt.

AlleAktien kvalitātes vērtējums Sinphar Pharmaceutical Co ir 3/10.

Pašreiz nevar aprēķināt apgrozījumu Sinphar Pharmaceutical Co.

Pašlaik peļņa Sinphar Pharmaceutical Co nevar tikt aprēķināta.

Sinphar Pharmaceutical Co Ltd is a leading pharmaceutical manufacturer specializing in the research, development, manufacture, and marketing of pharmaceutical products. The company has over 40 years of experience in the industry and has earned an excellent reputation for its high quality and innovative products. The business model of Sinphar Pharmaceutical includes four main areas: generics, specialty drugs, natural products, and animal medicines. Each of these areas contributes to the overall growth of the company and offers customers a wide range of products to improve their health. In the generics area, Sinphar Pharmaceutical offers a comprehensive selection of cost-effective medications for various medical conditions. These generics are based on proven active ingredients approved by international organizations. Ongoing quality control ensures the effectiveness and safety of these products. Sinphar Pharmaceutical's specialty drugs include innovative products for rare diseases, cancer, and autoimmune diseases. These drugs are developed in collaboration with top global universities and research institutes and are at the forefront of medical research. The company aims to improve patients' quality of life. Sinphar Pharma's product range also includes natural remedies developed from traditional Chinese medicines. These products are based on natural ingredients and have proven to be highly effective in combating diseases such as colds, diabetes, and cholesterol. The company is committed to promoting users' well-being naturally. The company's final main area is the production of animal medicines. In this area, Sinphar Pharmaceutical offers high-quality products to combat parasites, bacterial, and viral infections. These are medications for the treatment of cattle, pigs, chickens, fish, and other animals in agriculture. The products are easy to administer and can help reduce the spread of infections. In addition to these four main areas, Sinphar Pharmaceutical also offers additional services such as custom research and development, clinical trials, and product registration to meet customers' needs. The company works closely with partners to provide outstanding services on a global level. The business model of Sinphar Pharmaceutical Co Ltd is based on offering a wide range of high-quality products that can be used by various customers in many industries. The diversity of the company's products is the result of years of research and development, during which the company has demonstrated its ability to produce innovative products that meet the needs of customers in today's fast-paced environment.

Sinphar Pharmaceutical Co izmaksā dividendes 0,20 TWD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Sinphar Pharmaceutical Co vai uzņēmums nedod dividendes.

Sinphar Pharmaceutical Co ISIN ir TW0001734002.

Sinphar Pharmaceutical Co simbols ir 1734.TW.

Pēdējo 12 mēnešu laikā Sinphar Pharmaceutical Co maksāja dividendes 1,00 TWD apmērā. Tas atbilst aptuveni 3,12 % dividendes ražībai. Nākamajos 12 mēnešos Sinphar Pharmaceutical Co plāno maksāt dividendes 1,00 TWD apmērā.

Sinphar Pharmaceutical Co pašreizējā dividendu rentabilitāte ir 3,12 %.

Sinphar Pharmaceutical Co maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos septembris, augusts, augusts, oktobris.

Sinphar Pharmaceutical Co pēdējo 20 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 1,00 TWD. Tas atbilst dividendes ražībai 3,12 %.

Sinphar Pharmaceutical Co tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Sinphar Pharmaceutical Co apmērā 1 TWD, kas tika izmaksāta 8.10.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 4.09.2024..

Pēdējās dividendes izmaksa notika 8.10.2024..

Gadā 2023, Sinphar Pharmaceutical Co izmaksāja 0,2 TWD dividendes.

Sinphar Pharmaceutical Co dividendes tiek izmaksātas TWD.